Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$9.71 +4.6%	$8.10	$5.01 ▼ $18.71	$55.32M	0.18	116,822 shs	78,617 shs
BTMD biote	$4.17 +1.7%	$3.95	$3.04 ▼ $8.35	$224.31M	1.21	167,188 shs	104,912 shs
MDWD MediWound	$20.05 +0.3%	$20.14	$14.14 ▼ $22.51	$216.15M	0.32	65,140 shs	62,851 shs
ORIC Oric Pharmaceuticals	$11.14 -0.4%	$8.70	$3.90 ▼ $14.67	$952.81M	1.54	784,082 shs	421,638 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	+4.63%	+2.43%	+24.49%	+57.37%	-19.42%
BTMD biote	+1.71%	-0.95%	+6.11%	+26.36%	-49.45%
MDWD MediWound	+0.25%	-4.93%	+1.37%	+17.25%	-1.38%
ORIC Oric Pharmaceuticals	-0.36%	-2.71%	+23.37%	+133.54%	+9.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.4105 of 5 stars	3.4	3.0	4.7	2.6	2.5	0.6
BTMD biote	3.3241 of 5 stars	3.5	2.0	0.0	2.7	3.3	1.3
MDWD MediWound	1.634 of 5 stars	3.5	1.0	0.0	1.6	0.8	0.6
ORIC Oric Pharmaceuticals	4.5232 of 5 stars	4.5	1.0	4.4	1.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.83	Moderate Buy	$20.00	105.97% Upside
BTMD biote	3.00	Buy	$8.00	91.85% Upside
MDWD MediWound	3.00	Buy	$32.25	60.85% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$18.57	66.71% Upside

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, MDWD, and BTMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/6/2025	ORIC Oric Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC Oric Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$199.73M	0.29	N/A	N/A	($16.89) per share	-0.57
BTMD biote	$197.19M	1.16	$0.78 per share	5.35	($2.78) per share	-1.50
MDWD MediWound	$20.22M	10.72	N/A	N/A	$2.89 per share	6.94
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
BTMD biote	$3.16M	$0.61	6.84	7.72	N/A	10.93%	-19.44%	20.12%	8/6/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)

Latest ATRA, ORIC, MDWD, and BTMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BTMD biote	$0.06	N/A	N/A	N/A	$49.52 million	N/A
8/13/2025	Q2 2025	MDWD MediWound	-$0.55	N/A	N/A	N/A	$5.68 million	N/A
8/11/2025	Q2 2025	ATRA Atara Biotherapeutics	-$0.32	N/A	N/A	N/A	$4.23 million	N/A
8/11/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	N/A	N/A	N/A	N/A	N/A
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/7/2025	Q1 2025	BTMD biote	$0.06	$0.08	+$0.02	$0.37	$47.25 million	$48.99 million
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BTMD biote	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.57	0.57
BTMD biote	N/A	1.42	1.14
MDWD MediWound	N/A	2.15	1.99
ORIC Oric Pharmaceuticals	N/A	12.00	12.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
BTMD biote	21.68%
MDWD MediWound	46.83%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	4.00%
BTMD biote	24.00%
MDWD MediWound	9.20%
ORIC Oric Pharmaceuticals	6.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
BTMD biote	194	54.71 million	41.58 million	Not Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
ORIC Oric Pharmaceuticals	80	85.22 million	79.41 million	Optionable

ATRA, ORIC, MDWD, and BTMD Headlines

Recent News About These Companies

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

July 15 at 10:44 PM | finance.yahoo.com

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

July 15 at 10:56 AM | zacks.com

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock ... - Nasdaq

July 13, 2025 | nasdaq.com

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

July 11, 2025 | zacks.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% - Here's What Happened

July 11, 2025 | marketbeat.com

Ladenburg Thalmann Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Buy Recommendation

July 9, 2025 | msn.com

Brokerages Set Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $19.17

July 9, 2025 | americanbankingnews.com

Oric Pharmaceuticals (NASDAQ:ORIC) Now Covered by LADENBURG THALM/SH SH

July 8, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Recommendation of "Buy" from Analysts

July 6, 2025 | marketbeat.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 5, 2025 | morningstar.comM

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Metastatic Prostate Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 3, 2025 | theglobeandmail.com

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 10% Higher - Time to Buy?

July 2, 2025 | marketbeat.com

Oric Pharmaceuticals Inc. Advanced Charts | ORIC | Barron's

June 28, 2025 | barrons.com

Oric Pharmaceuticals Shows Market Leadership With Jump To 93 RS Rating

June 25, 2025 | msn.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $10,340.00 in Stock

June 25, 2025 | insidertrades.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 1,034 Shares

June 24, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $340,893.00 in Stock

June 24, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Insider Buying Activity

June 24, 2025 | marketbeat.com

Angie You Purchases 1,403 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

June 24, 2025 | insidertrades.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 26,597 Shares

June 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
The Meteoric Rise of Rocket Lab: A Space Stock to Watch
By Ryan Hasson | July 11, 2025
View The Meteoric Rise of Rocket Lab: A Space Stock to Watch
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
3 Infrastructure Stocks Riding the U.S. Building Boom
By Chris Markoch | July 14, 2025
View 3 Infrastructure Stocks Riding the U.S. Building Boom

ATRA, ORIC, MDWD, and BTMD Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$9.71 +0.43 (+4.63%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$9.70 -0.01 (-0.05%)

As of 07/17/2025 07:33 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

biote NASDAQ:BTMD

$4.17 +0.07 (+1.71%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$4.18 +0.01 (+0.24%)

As of 07/17/2025 04:04 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

MediWound NASDAQ:MDWD

$20.05 +0.05 (+0.25%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$20.02 -0.03 (-0.15%)

As of 07/17/2025 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Oric Pharmaceuticals NASDAQ:ORIC

$11.14 -0.04 (-0.36%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$11.16 +0.02 (+0.22%)

As of 07/17/2025 07:52 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time